Jean Bennett and Albert Maguire are married. They are also the reason several hundred people who were going blind have retained their sight.

Their lab at the University of Pennsylvania spent the better part of the 1990s working out the technical details of a gene therapy for Leber congenital amaurosis — a genetic disease that strips away retinal function in childhood, usually ending in total blindness before adulthood. They tried it first in dogs. A group of Swedish Briard puppies, born with the same genetic defect, had their sight restored. Bennett and Maguire adopted them.

In 2007, Maguire administered the first injection into a human patient — a 26-year-old woman at Children’s Hospital of Philadelphia. A decade later, in December 2017, the FDA approved Luxturna: the first gene replacement therapy for an inherited disease in US history. At the April 2026 Breakthrough Prize ceremony in Los Angeles, Bennett, Maguire, and their longtime collaborator Katherine High shared the Breakthrough Prize in Life Sciences for that work. Some of the patients who received Luxturna have since qualified for driver’s licenses.

What the Disease Does, and What the Therapy Fixes

Leber congenital amaurosis is caused by a mutation in the RPE65 gene, which produces a protein the retina needs to complete its visual cycle — the process by which light hitting the eye becomes an electrical signal sent to the brain. Without functional RPE65, that cycle breaks. The retina can still receive light but cannot convert it into anything the brain can read. Patients lose light sensitivity progressively, typically experiencing severe vision loss before 18 and total blindness shortly after.

The therapy developed by Bennett, High, and Maguire uses a modified adeno-associated virus — a delivery vehicle that can carry genetic material without triggering immune rejection — to insert a working copy of the RPE65 gene directly into retinal cells via subretinal injection. One treatment per eye, administered days apart. The corrected cells begin producing the protein, the visual cycle resumes, and patients who could previously see only in very bright light start perceiving details they had never been able to make out.

Patients in early clinical trials described seeing snow for the first time. One described seeing the moon. Another saw stars. The disease affects an estimated 1,000 to 3,000 people in the United States — a population small enough that commercial development alone would never have funded the three decades of research required to reach them. Katherine High, who served as the founding director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics at CHOP and is now CEO of RhyGaze, a gene therapy company based in Philadelphia and Switzerland, helped bridge the gap between academic science and the regulatory pathway that eventually made Luxturna approvable. Bennett, 71, and Maguire, 66, remain emeritus professors at Penn. The therapy they built together has been approved not just by the FDA but by regulators in Europe, where Novartis licensed it for distribution outside the US.

Why Forty Years Is the Point

Bennett joined Penn’s faculty in 1992. The first human clinical trial ran in 2007. FDA approval came in 2017. The prize arrived in 2026. That timeline — three-plus decades from academic lab to pharmacy — accurately describes how foundational biomedical research moves when it is not being chased by a commercial deadline.

This is the argument Yuri Milner has made consistently in designing the Breakthrough Prize. Most private funding in science rewards proximity to an application. Grants chase outcomes. Venture capital chases returns on timescales measured in years, not decades. The researchers who spend thirty years on a disease affecting fewer than 3,000 Americans are working outside the incentive structures that normally sustain scientific careers. They are building a cathedral, in Milner’s phrase from the 2026 prize announcement — “on foundations laid down by the giants who came before them..”

The Prize was designed to recognize exactly that kind of researcher: contributors whose work is foundational rather than immediately monetizable, operating on timescales that most institutional funding structures struggle to sustain. Milner’s own training as a theoretical physicist shaped the conviction directly. He spent years in a discipline where the gap between discovery and application is routinely measured in generations — where the mathematics developed in one century becomes the engineering of the next.

What the Prize adds to recognition is visibility. A $3 million award, handed out on a Hollywood stage in front of an audience that includes the CEOs of Nvidia and OpenAI alongside film and music performers, reaches a different public than a journal publication or a tenure committee commendation. That visibility matters because public understanding of what science produces determines, over time, what science gets funded.

The 2026 Life Sciences Class, Taken Together

Bennett, High, and Maguire shared the ceremony with two other Life Sciences prizes that, read alongside theirs, trace a consistent pattern in how Milner and the Breakthrough Prize Foundation think about which research deserves recognition.

Stuart Orkin and Swee Lay Thein received a prize for decades of work that eventually led to gene-editing treatments for sickle cell disease and beta-thalassemia — two inherited blood disorders that together affect millions of people globally, with the heaviest burden falling on populations in sub-Saharan Africa, South Asia, and the Mediterranean. Thein identified a genetic region linked to elevated fetal hemoglobin production in adults, a trait that naturally softens the severity of both conditions. Orkin identified BCL11A, the specific gene that suppresses fetal hemoglobin after birth. Their combined findings gave researchers a precise molecular target: silence BCL11A, allow protective fetal hemoglobin to persist, and the disease becomes dramatically more manageable. Gene-editing therapies built on exactly that logic have since reached patients and received regulatory approval.

Rosa Rademakers and Bryan Traynor were recognized for identifying the C9orf72 gene mutation as the most common known genetic cause of both ALS and frontotemporal dementia — two conditions that had long resisted genetic explanation and had largely been treated as separate diseases. The discovery that a single mutation could drive both redirected an entire research field toward a testable, actionable target. Clinical trials targeting C9orf72 are now running.

Each of the three prizes honored research that required patience measured in decades, produced results that could not have been commercially predicted at the outset, and has since moved from academic publication toward patients who had no other options.

What the Eureka Manifesto Said About Biology

In his Eureka Manifesto, Milner identified life sciences as one of the deepest mismatches in all of science — research that is profound in its importance to human welfare and chronically underfunded relative to that importance. The book makes the case that directing serious capital toward fundamental biological research is one of the highest-return investments a civilization can make, precisely because the downstream benefits cannot be predicted from the research itself at the time it is being done.

Luxturna illustrates this directly. Bennett’s early work in the 1990s was about understanding how a specific protein interacts with the retina. It was a basic science question about a poorly understood mechanism. It became a therapy because the science pointed there, because the researchers followed it long enough, and because the clinical and regulatory infrastructure existed to translate the findings. The Giving Pledge commitment Milner made alongside his wife Julia in 2012 formalized this philosophy at the level of personal wealth: invest in scientists, not just projects. Trust the researchers building foundations before the applications are visible.

That framing has practical consequences for how the Prize is structured. It does not restrict its recognition to research that has already produced a commercial product. It recognizes the discovery, the mechanism, the molecular target — the work that makes products possible years or decades later. The 2026 Life Sciences class is evidence that this distinction is not semantic. All three prize-winning programs produced fundamental knowledge long before they produced clinical outcomes.

The Cathedral and the Patient

At the 2026 ceremony, Anne Hathaway and Alex Honnold presented a video about Baby KJ — KJ Muldoon, a child born with carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disease in which the liver cannot process ammonia properly. Without treatment, the ammonia buildup becomes toxic to the brain. KJ was only days old when he was diagnosed and spent his first ten months at the hospital. His doctors at Children’s Hospital of Philadelphia developed a personalized CRISPR-based gene therapy using base-editing techniques pioneered by previous Breakthrough Prize laureate David Liu — a one-time treatment designed specifically around KJ’s individual mutation. He has since been walking, talking, and meeting developmental milestones that were once uncertain.

The connection between KJ’s treatment and the research honored at the same ceremony runs through the logic of the entire evening. Liu’s base-editing work, recognized by a prior Breakthrough Prize, made KJ’s therapy possible. Bennett, High, and Maguire’s gene therapy work, recognized this year, established the delivery mechanisms and regulatory precedents that personalized gene therapies now build on. The cathedral metaphor Milner used in his statement holds: each laureate’s work is a section of a structure that no single researcher could complete alone, and whose full dimensions no single generation could see.

Milner has described the Prize as a public claim about value — about what a society decides deserves recognition and therefore resources. A researcher who spends forty years on a disease affecting a few thousand people, without a commercial path in sight, is making a bet that the science matters more than the return. The Prize says that bet was right. Baby KJ, walking and talking at a Hollywood ceremony that his existence helped explain, is what it looks like when that bet pays out.